Clinical Trial

Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

Name: Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study) — clinical trial record (NCT06779695)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.

Trial Details

NCT Number	NCT06779695
Lead Sponsor	Korea University Anam Hospital Collaborators: Korea University Ansan Hospital, Mediplex Sejong Hospital, Chungnam National University Hospital, Chonnam National University Hospital, Kyung Hee University Hospital at Gangdong, Kyungpook National University Hospital, Korea University Guro Hospital, InjeUniversityIlsanPaikHospital, Wonkwang University Hospital, Keimyung University Dongsan Medical Center
Conditions	Atrial Fibrillation (AF)
Enrollment	2,000 participants
Start Date	2024-04-21
Primary Completion	2028-09-30 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-01-16